» Articles » PMID: 24021349

Phase II Study of Temozolomide in Combination with Topotecan (TOTEM) in Relapsed or Refractory Neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma Study

Abstract

Purpose: To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma.

Patients And Methods: This multicenter, non-randomised, phase II study included children with neuroblastoma according to a two-stage Simon design. Eligibility criteria included relapsed or refractory, measurable or metaiodobenzylguanidine (mIBG) evaluable disease, no more than two lines of prior treatment. Temozolomide was administered orally at 150mg/m(2) followed by topotecan at 0.75mg/m(2) intravenously for five consecutive days every 28days. Tumour response was assessed every two cycles according to International Neuroblastoma Response Criteria (INRC), and reviewed independently.

Results: Thirty-eight patients were enroled and treated in 15 European centres with a median age of 5.4years. Partial tumour response after two cycles was observed in 7 out of 38 evaluable patients [ORR 18%, 95% confidence interval (CI) 8-34%]. The best ORR whatever the time of evaluation was 24% (95% CI, 11-40%) with a median response duration of 8.5months. Tumour control rate (complete response (CR)+partial response (PR)+mixed response (MR)+stable disease (SD)) was 68% (95% CI, 63-90%). The 12-months Progression-Free and Overall Survival were 42% and 58% respectively. Among 213 treatment cycles (median 4, range 1-12 per patient) the most common treatment-related toxicities were haematologic. Grade 3/4 neutropenia occurred in 62% of courses in 89% of patients, grade 3/4 thrombocytopenia in 47% of courses in 71% of patients; three patients (8%) had febrile neutropenia.

Conclusion: Temozolomide-Topotecan combination results in very encouraging ORR and tumour control in children with heavily pretreated recurrent and refractory neuroblastoma with favourable toxicity profile.

Citing Articles

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V J Clin Oncol. 2024; 42(10):1135-1145.

PMID: 38190578 PMC: 11003502. DOI: 10.1200/JCO.23.00458.


Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series.

De Ioris M, Fabozzi F, Del Bufalo F, Del Baldo G, Villani M, Cefalo M Sci Rep. 2023; 13(1):19295.

PMID: 37935707 PMC: 10630499. DOI: 10.1038/s41598-023-44993-9.


Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.

Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E J Immunother Cancer. 2023; 11(9).

PMID: 37775116 PMC: 10546160. DOI: 10.1136/jitc-2023-007174.


Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.

Olgun N, Cecen E, Ince D, Kizmazoglu D, Baysal B, Onal A Front Oncol. 2023; 12:1041443.

PMID: 36620564 PMC: 9816792. DOI: 10.3389/fonc.2022.1041443.


Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry.

Jazmati D, Hero B, Thole-Kliesch T, Merta J, Deubzer H, Baumer C Curr Oncol. 2022; 29(11):8222-8234.

PMID: 36354709 PMC: 9689739. DOI: 10.3390/curroncol29110649.